Zoetis shares drop 52% in 12 months but offer 50% upside with steady dividends and offsetting growth segments.

Zoetis, spun off from Pfizer in 2013, has seen its share price fall 52% over the past year, now trading at just 12 times trailing earnings. Despite slowing revenue growth of 3% in Q1 2026, growth in international and livestock segments is balancing weakness in U.S. pet care. The company maintains a strong dividend growth streak of 12 years with a 2.8% yield supported by a solid payout ratio. Analysts see Zoetis as offering a compelling risk/reward profile with potential for 50% upside from current levels.